Newron Pharmaceuticals SpA banner

Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 18.3 CHF -2.03% Market Closed
Market Cap: CHf366.2m

Wall Street
Price Targets

NWRN Price Targets Summary
Newron Pharmaceuticals SpA

Wall Street analysts forecast NWRN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NWRN is 47.94 CHF with a low forecast of 25.25 CHF and a high forecast of 76.65 CHF.

Lowest
Price Target
25.25 CHF
38% Upside
Average
Price Target
47.94 CHF
162% Upside
Highest
Price Target
76.65 CHF
319% Upside
Newron Pharmaceuticals SpA Competitors:
Price Targets

Revenue
Forecast

37% / Year
Past Growth
38% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss
37% / Year
Past Growth
38% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss

For the last 14 years the compound annual growth rate for Newron Pharmaceuticals SpA's revenue is 37%. The projected CAGR for the next 4 years is 38%.

Operating Income
Forecast

N/A
Past Growth
55% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
N/A
Past Growth
55% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

The compound annual growth rate of Newron Pharmaceuticals SpA's operating income for the next 4 years is 55%.

Net Income
Forecast

N/A
Past Growth
57% / Year
Estimated Growth
Estimates Accuracy
-30%
Average Miss
N/A
Past Growth
57% / Year
Estimated Growth
Estimates Accuracy
-30%
Average Miss

The compound annual growth rate of Newron Pharmaceuticals SpA's net income for the next 4 years is 57%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NWRN's stock price target?
Price Target
47.94 CHF

According to Wall Street analysts, the average 1-year price target for NWRN is 47.94 CHF with a low forecast of 25.25 CHF and a high forecast of 76.65 CHF.

What is Newron Pharmaceuticals SpA's Revenue forecast?
Projected CAGR
38%

For the last 14 years the compound annual growth rate for Newron Pharmaceuticals SpA's revenue is 37%. The projected CAGR for the next 4 years is 38%.

What is Newron Pharmaceuticals SpA's Operating Income forecast?
Projected CAGR
55%

The compound annual growth rate of Newron Pharmaceuticals SpA's operating income for the next 4 years is 55%.

What is Newron Pharmaceuticals SpA's Net Income forecast?
Projected CAGR
57%

The compound annual growth rate of Newron Pharmaceuticals SpA's net income for the next 4 years is 57%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett